findmyKOL
Clinical trialNCT04096417UnknownPhase 2Interventional

Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

SponsorAcademic and Community Cancer Research UnitedEnrollment14FGFR1 Gene AmplificationFGFR1 Gene MutationFGFR1 Gene TranslocationFGFR2 Gene AmplificationFGFR2 Gene MutationFGFR2 Gene Translocation+13 more conditions
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial studies how well pemigatinib works in treating patients with colorectal cancer with mutations (alterations) in a FGFR gene and that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Pemigatinib may stop the growth of tumor cells by blocking FGFR, which is needed for cell growth.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Mayo Clinic in Arizona

    Scottsdale, Arizona, United States

  • Emory University Hospital/winship Cancer Institute

    Atlanta, Georgia, United States

  • Mayo Clinic in Rochester

    Rochester, Minnesota, United States

  • Duke University Medical Center

    Durham, North Carolina, United States

  • Vanderbilt University/ingram Cancer Center

    Nashville, Tennessee, United States

  • Aurora Cancer Care-Milwaukee West

    Wauwatosa, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Pemigatinib →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Aug 2020
Primary completion
13 May 2022
Completion
1 Dec 2025
Last update posted
21 Feb 2024
Registered enrollment
14
Registry id
NCT04096417
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.